Please assess the completion status of the following clinical trial:

Trial Title: Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Is scheduled to undergo primary unilateral TKA under general anesthesia.~* Has not previously undergone TKA in either knee.~* Has an American Society of Anesthesiologists Physical Status of I, II, or III.~* Is able to demonstrate motor function by performing a timed 20-meter walk unassisted, but with the optional use of a 4-legged walker for balance.~* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.~Exclusion Criteria:~* Has a planned concurrent surgical procedure (eg, bilateral TKA).~* Has a pre-existing concurrent acute or chronic painful/restrictive physical condition that may require analgesic treatment in the postoperative period for pain.~* Has a contraindication or a known or suspected history of hypersensitivity or idiosyncratic reaction to required study medications.~* Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.~* Has taken NSAIDs within 10 days prior to the scheduled surgery.~* Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).~* Has been administered bupivacaine within 5 days prior to the scheduled surgery.~* Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.~* Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.~* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.~* Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.~* Has uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments.~* Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature. Has any chronic condition or disease that would compromise neurological or vascular assessments.~* Had a malignancy in the last year, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.~* Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.~* Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.~* Has undergone 3 or more surgeries within 12 months.~* Has a body mass index (BMI) \>38 kg/m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1, Group 1: HTX-011 (Type: EXPERIMENTAL): HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
- Cohort 1, Group 2: HTX-011 (Type: EXPERIMENTAL): HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
- Cohort 1, Group 3: Saline Placebo (Type: PLACEBO_COMPARATOR): Saline placebo via injection
- Cohort 1, Group 4: Bupivacaine HCI (Type: ACTIVE_COMPARATOR): Bupivacaine HCl without epinephrine, 125 mg via injection
- Cohort 2, Group 1: HTX-011 (Type: EXPERIMENTAL): HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
- Cohort 2, Group 2: HTX-011 + Ropivacaine (Type: EXPERIMENTAL): HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
- Cohort 2, Group 3: Saline Placebo (Type: PLACEBO_COMPARATOR): Saline placebo via injection
- Cohort 2, Group 4: Bupivacaine HCI (Type: ACTIVE_COMPARATOR): Bupivacaine HCl without epinephrine, 125 mg via injection

Based on this trial design, predict the completion outcome and termination type (if applicable).